A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive–Compulsive Disorder
Authors:
- 1 September 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 27 (7) , 640-651
Abstract
Objectives: Sudden and severe onset of obsessive–compulsive disorder (OCD) may present secondary to infectious and/or immune-mediated triggers. We assessed the preliminary efficacy, tolerability, and safety of azithromycin compared with placebo in the treatment of OCD and associated symptoms in children with pediatric acute-onset neuropsychiatric syndrome (PANS). Methods: Thirty-one youth aged 4–14 years (M = 8.26 ± 2.78 years, 62.5% male) were randomized to receive either placebo or azithromycin for 4 weeks (10 mg/kg up to 500 mg per day). Both groups were administered twice daily probiotics. The primary outcome, obsessive–compulsive symptom severity, was assessed using the OCD Clinical Global Impressions Severity (CGI-S OCD) and Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS). Results: Participants in the azithromycin group (n = 17) showed significantly greater reductions in OCD severity on the CGI-S OCD than the placebo group (n = 14) posttreatment (p = 0.003), although there were no significant differences on the CY-BOCS. Significantly more participants in the azithromycin condition met treatment responder criteria on the CGI-I OCD at the end of week 4 (41.2%, n = 7) in comparison to the placebo group (7.1%, n = 1; p = 0.045). Tic severity moderated treatment response, with greater tic severity being associated with enhanced treatment response on the CGI-S OCD. Azithromycin was well tolerated with minimal adverse effects and no study dropouts due to side effects. However, the azithromycin group showed a trend toward significantly greater electrocardiography QTc (p = 0.060) at the end of week 4, and significantly more reports of loose or abnormal stools (p = 0.009). Conclusion: This double blind pilot study suggests that azithromycin may be helpful in treating youth meeting the PANS diagnosis, especially those with elevated levels of both OCD and tic symptoms. Azithromycin was well tolerated, but the potential for cardiac risks suggests that additional monitoring may be needed to ensure safety.Keywords
This publication has 44 references indexed in Scilit:
- Clinical Factors Associated with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal InfectionsThe Journal of Pediatrics, 2012
- Reduced anxiety-like behavior and central neurochemical change in germ-free miceNeurogastroenterology & Motility, 2010
- Immunomodulatory Effects of Macrolide Antibiotics – Part 1: Biological MechanismsRespiration, 2010
- Comparison of Clinical Characteristics of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections and Childhood Obsessive-Compulsive DisorderJournal of Child and Adolescent Psychopharmacology, 2010
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disordersBiological Psychiatry, 2005
- Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and ticsBiological Psychiatry, 2004
- Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive DisorderAmerican Journal of Psychiatry, 2003
- Childhood-onset obsessive-compulsive disorderClinical Psychology Review, 2001
- Measurement of the QT interval and the risk associated with QTc interval prolongation: A reviewThe American Journal of Cardiology, 1993